Table 1.
Clinical characteristics of the patients.
| Parameter | Result |
|---|---|
| Patients | 36 |
| Demographic characteristics | |
| Males:females (ratio) | 20:16 (1.2) |
| Median age at the time of CAR-T-cell therapy (range) | 68.5 (27–79) |
| Initial diagnosis | |
| DLCBL | 36 (100%) |
| Primary (de novo) DLBCL | 18 (50%) |
| Secondary/transformed DLBCL | 18 (50%) |
| FL | 13 (36%) |
| CLL/SLL | 3 (8%) |
| MZL | 1 (3%) |
| Other | 1 (3%) |
| Initial lymphoma stage | 36 |
| I | 1 (3%) |
| II | 5 (14%) |
| III | 6 (17%) |
| IV | 17 (47%) |
| Unknown | 7 (19%) |
| B-symptoms at lymphoma diagnosis | 22 (61%) |
| Radiotherapy before lymphapheresis | 12 (33%) |
| Radiotherapy as bridging between lymphapheresis and CAR-T-cell infusion | 4 (11%) |
| Previous hematopoietic stem-cell transplantation before CAR-T-cell therapy | 22 (61%) |
| Autologous SCT | 21 (58%) |
| Allogeneic SCT | 1 (3%) |
| IPI for lymphoma patients | 36 |
| 1 | 0 (0%) |
| 2 | 3 (8%) |
| 3 | 4 (11%) |
| 4 | 3 (8%) |
| 5 | 1 (3%) |
| Unknown | 25 (70%) |
| Number of treatment lines before CAR-T-cell therapy | |
| 2 | 22 (61%) |
| 3 | 9 (25%) |
| >3 | 5 (14%) |
CAR-T: chimeric antigen receptor T cell; DLCBL: diffuse large B-cell lymphoma; FL: follicular lymphoma; CLL: chronic lymphocytic leukemia; SLL: small lymphocytic lymphoma; MZL: marginal-zone lymphoma; SCT: hematopoietic stem-cell transplantation; IPI: International Prognostic Index.